# Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)

> **NCT01224626** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 41 (actual)

## Conditions studied

- Vancomycin Resistance Enterococcus Faecium

## Interventions

- **DRUG:** Zyvox (linezolid)

## Key facts

- **NCT ID:** NCT01224626
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2012-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01224626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01224626, "Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01224626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*